Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
2014-February Volume 9 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
2014-February Volume 9 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19

  • Authors:
    • Xiu-Ran Wang
    • Guang-Mou Yan
    • Rui Zhang
    • Xu-Long Lang
    • Yan‑Ling Yang
    • Xiao-Yan Li
    • Si Chen
    • Jing Qian
    • Xing-Long Wang
  • View Affiliations / Copyright

    Affiliations: College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130062, P.R. China, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Institute of Military Veterinary, AMMS, Changchun 130122, P.R. China, State Key Laboratory of Special Economic Animal Molecular Biology, Institute of Special Economic Animal and Plant Science, Chinese Academy of Agricultural Sciences, Changchun 130122, P.R. China
  • Pages: 653-658
    |
    Published online on: November 18, 2013
       https://doi.org/10.3892/mmr.2013.1810
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Brucellosis is an infectious disease affecting humans and animals worldwide. Effective methods of control include inducing immunity in animals by vaccination and elimination. Brucella abortus S19 is one of the popular vaccines for control of cattle brucellosis, as it has low virulence. In this paper, allelic exchange plasmids of wzm and wzt genes were constructed and partially knocked out to evaluate the effects on the induction of immunity to Brucella abortus S19 mutants. Cytokine secretion in vitro, INF-γ induction in vivo and antibody dynamics were evaluated. These data suggested that the immunity-eliciting ability of the wzm and wzt gene deletion mutants was similar, although reduced compared with the S19 strain. The results demonstrated that the wzt gene may be more important in the regulation of the induction of immunity than the wzm gene.

Introduction

Brucella species, the cause of brucellosis in humans and animals, are facultative intracellular bacteria. Brucella invades phagocytic and non-phagocytic cells and survives inside the host cells (1,2). The properties of the intracellular lifestyle of Brucella limit the number of antibiotics that are effective against these organisms once they form Brucella-containing vacuoles (BCVs) (3). Under most conditions, control of brucellosis in animal reservoirs is achieved via vaccination. Human brucellosis has also been controlled by immunization and culling within cattle, goat and sheep herds (4,5).

Currently there are no vaccines for humans and the useful vaccines for livestock are (Brucella abortus) B. abortus S19 and RB51 for cattle and Brucella melitensis (B. melitensis) Rev1 for small ruminants (6,7). B. abortus S19 has been widely used to prevent cattle brucellosis, as it usually has low virulence. However, it is infectious in humans and always causes abortion when used in pregnant animals (8,9). Since B. abortus S19 induces antibodies to the O-polysaccharide, it is difficult to distinguish from wild-type infection. The relevant diagnostic antigen is the smooth lipopolysaccharide (LPS) present in field strains, as well as in B. abortus S19 and B. melitensis Rev 1 (10–12). The development of a safe and efficacious vaccine that conquers this serological obstacle may have a broad impact on public health.

LPS provides bacterial resistance to antimicrobial attacks and modulates the host immune response, which makes it an important virulence factor for survival and replication in the host cell (1,13). It provides Brucella with resistance to innate immunity antibacterial responses by inhibiting complement and antibacterial peptide attacks, and by preventing the synthesis of immune mediators (14–16). The O-chain appears to help Brucella to invade cells in the early entry stage (17).

Brucellae without O-side chains are termed as rough or ‘R’ strain. R Brucella species or mutants lack the antigenic O-side chain and they do not induce anti-O-side chain antibodies. Currently, vaccinated hosts are difficult to distinguish from wild-type-infected hosts by common serological tests. It has been shown that Brucella R mutants are attenuated; therefore, R mutants have potential for use as vaccines (18–22). Several genes of B. melitensis 16M LPS synthesis were analyzed and ABC-type transporter (integral membrane protein, Wzm) and ABC-type transporter (ATPase domain, Wzt) were determined to be putative components of the ABC transporter system. The wzm/wzt mutant was proven to lead to the absence of the O-side-chain on the bacterial surface (23,24).

The wzt mutant of B. melitensis 16M was evaluated and determined to have virulence-reducing potential in a mouse model (25). In recent years, LPS has been shown to interfere with major histocompatibility complex (MHC)-II presentation, which inhibits peptide presentation in cells (13,16). In the present study, we constructed wzm and wzt gene partial deletion mutants with no DNA marker addition, in order to estimate the survival in vivo and the serological response. This may provide us with an improved understanding of the effect of wzm and wzt genes on the induction of immunity caused by the S19 vaccine strain.

Materials and methods

Bacterial strains and growth conditions

Escherichia coli DH5α strain was grown on Luria-Bertani broth (LB) agar at 37°C. Brucella strains B. abortus S19, Δwzm and Δwzt were grown on tryptic soy broth (TSB, Sigma, St. Louis, MO, USA) agar at 37°C. Ampicillin (100 μg/ml) and kanamycin (50 μg/ml) were added for plasmid screening if required. TSB medium (7% sucrose) was prepared for screening of allelic-exchange mutants.

Construction of wzt and wzm mutants

The allelic exchange plasmids were constructed by pBKCMV (kanr) with a sacB gene and fragments upstream and downstream of target genes. The sacB gene along with its promoter was amplified from pIBP279 (provided by Nanjing Agricultural University) using PCR methods and ligated into pBKsacB to construct pBKsacBwzm and pBKsacBwzt (Table I). Competent cells of B. abortus S19 were prepared and the constructed plasmid was electroporated into the cells at 1,500 kV [1-mm gap cuvette; BTX, Harvard Apparatus, Inc, Holliston, MA, USA]. Subsequently, 1 ml SOC (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM CaCl2, 10 mM MgSO4 and 20 mM glucose) was added and cells were grown under agitation at 28°C for 24 h and then plated on TSB agar (kanr) and cultured for 96 h at 28°C. The mutants were confirmed using PCR. The phenotype of the mutants was then determined by agglutination with acriflavine at a dilution of 1:100 (26).

Table I

Bacteria and plasmids.

Table I

Bacteria and plasmids.

Strain or plasmidPhenotype and/or genotypeSource
Strains
B. abortus S19Vaccine strain, smoothIVDC
 B. abortus ΔwzmB. abortus S19 ΔwzmThis study
 B. abortus ΔwztB. abortus S19 ΔwztThis study
Plasmid
 pBKCMVKanamycinStratagene
 pIBP279With sacB geneNJAU

[i] IVDC, China Institute of Veterinary Drug Control, Beijing, China; NJAU, Nanjing Agricultural University, Nanjing, China.

Animals

The 4–6-week-old female specific pathogen-free (SPF) BALB/c mice were provided by the animal centre of Jilin University (Changchun, China). Mice were bred in the animal facilities with filtered air in a restricted-access room and under pathogen-limited conditions. Mice were acclimatised for a minimum of one week prior to the experiment and water and food was provided ad libitum. The animal experiments were approved by the Center of Laboratory Animals, Jilin University, China.

Serological test and antibody dynamics

Female BALB/c mice of 6–8 weeks of age were housed with water and food. Animals were randomly allocated to groups and acclimatised for 1 week prior to the initiation of experiments (n=5). To prepare the inoculated samples, bacteria were suspended in PBS and adjusted to the appropriate 108 CFU/ml in the same buffer. Blood samples from BALB/c mice were collected and allowed to clot for 12 h at 4°C and centrifuged. Serum was divided into Eppendorf tubes (Eppendorf, Hamburg, Germany), and stored at −80°C. The Rose Bengal plate agglutination test (RBPT, Harbin Pharmaceutical Group Bio-vaccine Co., Harbin, China) was carried out by mixing 30 μl serum and 30 μl antigen, and the reaction was observed after 4 min.

The IgG antibody titer was estimated by indirect enzyme-linked immunosorbent assay (ELISA). The 96-well plates were coated by diluted Brucella antigens S19, Δwzm and Δwzt (pH 9.6, 0.05 M carbonate buffer 100 μl each well, antigen concentration 108 pfu), at 4°C overnight. The plate was washed with 200 μl PBST buffer (pH 7.4, 0.01 M PBS: Tween-20, 1:1,000) three times, for 3 min each time, and then blocked by 100 μl 1% BSA (pH 7.4) and incubated at 37°C for 1 h followed by three washes with PBST. The sera samples diluted from 1:100 to 1:3,200 were added and incubated at 37°C for 1 h. After three washes with PBST, enzyme-labeled goat anti-mouse IgG (1:5,000) was added and incubated at 37°C for 1 h and then washed with PBST three times. TMB substrate solution (100 μl) was then added and incubated at 37°C for 10 min (in light). Then, 50 μl 2 M sulfate buffer was added to stop the reaction, followed by detection of optical density (OD) at 490 nm. The antibody titer was described as the diluted ratio controlled by the S/N ratio. If the S/N ratio was ≥2.1, the sample of serum was considered positive. The S/N ratio was calculated as: (sample - blank)OD490/(negative - blank)OD490.

Lymphocyte proliferation

After injecting antigens for 4 weeks, the spleens of mice were removed under sterile conditions, put in a sterile Petri dish with 4 ml lymphocyte separation liquid (Dakewe Biotech Co., Shenzhen, China) and then ground with a disposable syringe core in a 200-mesh nylon sieve (74 μm pore diameter). The spleen cell suspension was then added to a sterile centrifuge tube and 500 μl of RPMI-1640 medium was gradually added. The cells were then centrifuged for 10 min at 300 × g. The lymphocyte layer was placed into new centrifuge tubes, resuspended in 10 ml of RPMI-1640 and centrifuged for 2 min at 1,500 rpm. Subsequently, 5 ml of 0.15 M Tris-NH4Cl solution was added to the cells and the cells were centrifuged at 200 × g for 5 min after 5 min incubation at room temperature. The supernatant was removed and the cells were washed twice with RPMI-1640. The lymphocytes were resuspended by RPMI-1640 with 5% FBS and the cell concentration was adjusted to 2×106/ml.

The lymphocytes (1×104 per well in triplicate) were incubated with corresponding antigens (multiplicity of infection of 200 CFU/cell; PBS in RPMI-1640 medium as negative control) in 96-well plates at 37°C in an atmosphere containing 5% (v/v) CO2. After 24 h of culture, 20 μl MTS solution was added to each well and the cells were incubated for 4 h at 37°C in an atmosphere containing 5% (v/v) CO2. The absorbance (optical density, OD) at 490 nm was recorded. Lymphocyte proliferation ratio (IS) was calculated as: (OD-OD1640)/(ODPBS-OD1640).

Cytokine induction in vitro and in vivo

The lymphocyte cells (1×105 per well in triplicate) were incubated with corresponding antigens (multiplicity of infection of 200 CFU/cell; PBS in RPMI-1640 as negative control) for 24 h in 24-well plates at 37°C in an atmosphere containing 5% (v/v) CO2. The cell culture supernatants were collected and stored at −80°C. The cytokine levels were analyzed using R&D Quantikine TNF-α, INF-γ, IL-2, IL-4 and IL-10 kits according to the manufacturer's instructions (Minneapolis, MN, USA). The INF-γ levels of serum were estimated using the same method.

Statistical analysis

The data were analyzed using Original 7.5 software and presented as the means ± standard deviation (mean ± SD). Significant differences between the groups were identified by one-way ANOVA (significant difference, P<0.01 and P<0.05).

Results

Screening of mutant strains

In order to obtain partial mutants of wzm and wzt genes, the plasmids pBKsacBwzm and pBKsacBwzt were constructed as shown in Fig. 1A–C. The plasmid was then electroporated into B. abortus S19 cells. The transformed samples were plated on TSB agar medium (Kanr) for the first screen. The colonies were added to TSB medium and detected by PCR with sacB primers for the second screen. The positive culture was spread on 7% sucrose TSA medium for the allelic exchange screen (27). The colonies from 7% sucrose TSB agar medium were inoculated into TSB medium and screened by pre-gene primers (wzm or wzt gene) for the fourth screen. If the cells were mutants, the target gene was found to be shorter than the pre-gene. The positive mutants were those with only one band ~300 bp after the screening process (Fig. 2). The putative-positive mutants were inoculated into TSB medium (Kanr) to remove the false-positive mutants.

Figure 1

The construction of allelic exchange plasmids, and the mutant site descriptions at Brucella abortus (B. abortus) S19 chromosome. (A) Allelic exchange diagram of constructed plasmids and chromosome of S19. (B) Constructs of B. abortus Δwzm. (C) Constructs of B. abortus Δwzt. The number is the locus of the target genes on the chromosome from NCBI.

Figure 2

PCR detection of mutants. (A) The results of the fourth screen of Δwzm. Lane 6 is the false positive mutant and lane 9 is the putative positive mutant. (B) The results of the fourth screen of Δwzt. Lanes 4 and 5 are false positive mutants, and lane 12 is the putative positive mutant.

Mutant strains were rough mutants

After 30 passage cultures for genetic stability, the mutants were detected by PCR using target gene primers and upstream and downstream fragment primers, and the sequences were analyzed. The mutants were prepared for acriflavine agglutination. The Δwzm and Δwzt mutants were positive and the S19 strain was negative for acriflavine agglutination.

The results of the Rose Bengal plate agglutination test (RBT) showed positive and negative serum for the S19 group and the Δwzm and Δwzt groups, respectively. Therefore, Δwzm and Δwzt mutants did not elicit the antibody response to O-antigen in the host. These results indicated that the mutants were rough mutants.

Antibody dynamics

The IgG antibody changes of Δwzm and Δwzt mutants and S19 are shown from the second to the ninth week (Fig. 3). The antibody titer of Δwzm induced in mice was higher than S19 strain before the fourth week and after the sixth week. Particularly at the eighth week, the log10 antibody titer of mutant strains (S/N value of Δwzm and Δwzt mutants was 3.42±0.20 and 3.48±0.26, respectively) was significantly higher than the S19 strain (S/N=2.60±0.25, P<0.01). These results indicated that the rough mutants may induce higher antibody titers than the S19 strain.

Figure 3

Antibody dynamic of positive control (S19), Δwzm and Δwzt mutants (n=5). **P<0.01 compared with the S19 group.

Lymphocyte proliferation

Lymphocyte proliferation is an important stage of the immune response. The results showed (Fig. 4) that the IS of S19 (7.13±1.09) was significantly higher than that of Δwzm (2.48±0.21) and Δwzt (1.38±0.07) mutants (P<0.01), which indicated that S19 induced higher lymphocyte proliferation. The IS of the Δwzm mutant was approximate to that of the Δwzt mutant (P>0.05). The disruption of wzm and wzt genes caused significantly decreased lymphocyte proliferation ability compared with the wild-type strain S19.

Figure 4

Lymphocyte proliferation (IS) of S19, Δwzm and Δwzt mutants by the MTS method (n=5). **P<0.01 vs. the wzm and wzt groups, respectively.

Cytokine secretion

The important immune-related cytokines INF-γ, IL-2, IL-4, IL-10 and TNF-α were detected in vitro (lymphocytes cultured in 24-well plates). The TNF-α, INF-γ, IL-2, IL-4 and IL-10 results showed that the cytokines induced by the Δwzm and Δwzt rough mutants were decreased and significantly lower than the S19 parent strain (P<0.01, Fig. 5A–E). IL-4 and TNF-α levels induced by Δwzt mutants were lower than those induced by Δwzm mutants (P<0.01) and INF-γ, IL-10 and IL-2 levels induced by Δwzt mutants were approximate to those induced by Δwzm mutants (P>0.05).

Figure 5

Cytokine concentrations of (A) INF-γ, (B) IL-2, (C) IL-4, (D) IL-10 and (E) TNFα (n=5). **P<0.01 compared with Δwzm and Δwzt, respectively; ##P<0.01 compared with negative control; ^^P<0.01, ^P<0.05 compared with Δwzt.

The INF-γ levels in serum were also detected from weeks 2 to 9. The curve (Fig. 6) showed that S19 and Δwzm rough mutant induced higher INF-γ levels (S19, 127.6±1.1 pg/ml at the third week; Δwzm rough mutant, 67.6±6.8 pg/ml at the fourth week), while the INF-γ levels induced by Δwzt rough mutants were lower than those of S19 and Δwzm (17.8±14.7 pg/ml on fourth week). The peak time of the INF-γ induction of Δwzm rough mutants (the fifth week was the peak of the curve) was delayed compared with S19 (peak of the curve was evident at the fourth week), and the Δwzt rough mutants were even more delayed. The concentrations of INF-γ induced by rough mutants were lower than those of S19, and the concentrations induced by Δwzt rough mutants were the lowest.

Figure 6

Changes of INF-γ levels of S19, Δwzm and Δwzt mutants in serum (n=5). **P<0.01 compared with Δwzt mutants group.

Discussion

In the present study, knockout of wzm and wzt genes caused the rough mutant. The wzm and wzt genes are the membrane-spanning homologs and the ATP-binding homologs of ABC-transporters involved in transmembrane export for O-polysaccharide chain biosynthesis (28). Previous studies on B. melitensis 16M observed that the mutant of wzm or wzt gene was a rough mutant (23–25). The acriflavine agglutination results indicated that the Δwzm and Δwzt mutants were rough mutants (21). Smooth strains did not induce acriflavine agglutination, suggesting that vaccination with these mutant strains may allow for differentiation between vaccinated and wild-type smooth strain-infected animals.

The cytokine-inducing ability of rough mutants was reduced. INF-γ is one of the most important cytokines in resistance to Brucella invasion, which enhances the macrophage bactericidal activity (29). The INF-γ levels induced by the Δwzm and Δwzt rough mutants was lower than those of the smooth strain S19 in vivo although not significantly lower. By contrast, INF-γ levels induced by the Δwzm and Δwzt mutants were significantly lower as compared to S19. IL-2 was detected in low quantities and IL-4 was detected at very low levels. IL-10 levels induced by S19 were significantly higher than those induced by the rough mutants, while IL-10 levels induced by the wzm mutant were higher than those of the wzt mutant.

Secretion of the inflammatory molecule TNF-α was reduced by rough mutants although not significantly as compared to S19. LPS is considered to be the most important modulator of TNF-α that is required for host defense against intracellular pathogens (30,31). The results showed that the disruption of LPS caused a reduction in TNF-α levels and spleen weights, and the spleen kinetics caused by rough mutants were significantly lower than those of the S19 strain. The TNF-α levels induced by the Δwzt mutant were lower than those induced by the Δwzm mutant.

These data indicate that the wzt gene may affect the host immune response indirectly. As previously reported, the wzm mutant provides efficient protection against Brucella invasion compared with mutants (25). Wzt disruption may affect the expression of more genes associated with the induction of immunity.

Acknowledgements

This study was funded by a project supported by the National Science and Technology Ministry (2010BAD04B03) and the Key Project of Chinese National Programs for Fundamental Research and Development (No. 2012CB722501).

References

1 

Cardoso PG, Macedo GC, Azevedo V and Oliveira SC: Brucella spp noncanonical LPS: structure, biosynthesis and interaction with host immune system. Microb Cell Fact. 5:132006. View Article : Google Scholar

2 

Rambow-Larsen AA, Petersen EM, Gourley CR and Splitter GA: Brucella regulators: self-control in hostil environment. Trends Microbiol. 17:371–377. 2009. View Article : Google Scholar

3 

Al-Tawfiq JA: Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther. 6:109–120. 2008. View Article : Google Scholar

4 

Pappas G, Papadimitrious P, Akritidis N, Christou L and Tsianos E: The new global map of human brucellosis. Lancet Infect Dis. 6:91–99. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa AM and Rice-Ficht AC: Brucellosis: the case for live, attenuated vaccines. Vaccine. 27:D40–D43. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Spink WW, Hall JW, Finstad J and Mallet E: Immunization with viable Brucella organisms. Results of a safety test in humans. B World Health Organ. 26:409–419. 1962.

7 

Perkins SD, Smither SJ and Atkins HS: Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 34:379–394. 2010.

8 

Monreal D, Grilló MJ, González D, Marín CM, De Miguel MJ, López-Goni I, Blasco JM, Cloeckaert A and Moriyón I: Characterization of Brucella abortus O-polysaccharide and core lipopolysaccharide mutant and demonstration that a complete core is required for rough vaccines to be efficient against Brucella abortus and Brucella ovis in the mouse model. Infect Immun. 71:3261–3271. 2003.

9 

Fugier E, Pappas G and Gorvel JP: Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Expert Rev Mol Med. 9:1–10. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Bundle DR, Cherwonogrodzky JW, Gidney MA, Meikle PJ, Perry MB and Peters T: Definition of Brucella A and M epitopes by monoclonal typing reagents and synthetic oligosaccharides. Infect Immun. 57:2829–2836. 1989.PubMed/NCBI

11 

Weynants V, Gilson D, Cloeckaert A, Tibor A, Denoel PA, Godfroid F, Limet JN and Letesson JJ: Characterization of smooth lipopolysaccharides and O-polysaccharides of Brucella species by competition binding assays with monoclonal antibodies. Infect Immun. 65:1939–1943. 1997.PubMed/NCBI

12 

Ugalde JE, Comerci DJ, Leguizamón MS and Ugalde RA: Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a new live rough-phenotype vaccine. Infect Immun. 71:6264–6269. 2003.PubMed/NCBI

13 

Lapaque N, Moriyon I, Moreno E and Gorvel JP: Brucella lipopolysaccharide acts as a virulence factor. Curr Opin Microbiol. 8:60–66. 2005. View Article : Google Scholar : PubMed/NCBI

14 

Eisenschenk FC, Houle JJ and Hoffmann EM: Serum sensitivity of field isolates and laboratory strains of Brucella abortus. Am J Vet Res. 56:1592–1598. 1995.PubMed/NCBI

15 

Velasco J, Bengoechae JA, Brandenberg K, Lindner B, Seydel U, Gonzalez D, Zahringer U, Moreno E and Moriyon I: Brucella abortus and its closest phylogenetic relative, ochrobacterum spp, differ in outer membrane permeability and cationic peptide resistance. Infect Immun. 68:3210–3218. 2000. View Article : Google Scholar

16 

Lapaque N, Forquet F, de Chastellier C, Mishal Z, Jolly G, Moreno E, Moriyon I, Heuser JE, He HT and Gorvel JP: Characterization of Brucella abortus lipopolysaccharide macrodomains as mega rafts. Cell Microbiol. 8:197–206. 2006.

17 

Porte F, Naroeni A, Ouahrani-Bettache S and Liautard JP: Role of the Brucella suis lipopolysaccharide O antigen in phagosomal genesis and in inhibition of phagosome-lysosome fusion in murine macrophages. Infect Immun. 74:1481–1490. 2003.

18 

Fernandez-Prada CM, Zelazowska EB, Nikolich M, Hadfield TL, Roop RM, Robertson GL and Hoover DL: Interactions between Brucella melitensis and human phagocytes: bacterial surface O-polysaccharide inhibits phagocytosis, bacterial killing and subsequent host cell apoptosis. Infect Immun. 71:2110–2119. 2003.

19 

Jiménez de Bagüés MP, Terraza A, Gross A and Dornand J: Different responses of macrophages to smooth and rough Brucella spp: relationship to virulence. Infect Immun. 72:2429–2433. 2004.PubMed/NCBI

20 

Moriyón I, Grilló MJ, Monreal D, González D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E and Blasco JM: Rough vaccines in animals brucellosis: structural and genetic basis and present status. Vet Res. 35:1–38. 2004.PubMed/NCBI

21 

Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G and Pasquali P: Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun. 73:4198–4204. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Haag AF, Myka KK, Arnold MF, Caro–Hernández P and Ferguson GP: Importance of lipopolysaccharide and cyclic β-1,2-glucans in Brucella-mammalian infections. Int J Microbiol. 2010:1245092010.

23 

Cloeckaert A, Grayon M, Verger JM, Letesson JJ and Godfroid F: Conservation of seven genes involved in the biosynthesis of the lipopolysaccharide O-side chain in Brucella spp. Res Microbiol. 151:209–216. 2000. View Article : Google Scholar : PubMed/NCBI

24 

Godfroid F, Cloeckaert A, Taminiau B, Danese I, Tibor A, de Bolle X, Mertens P and Letesson JJ: Genetic organization of the lipopolysaccharide O-antigen biosynthesis region of Brucella melitensis 16M (wbk). Res Microbiol. 151:655–668. 2000. View Article : Google Scholar : PubMed/NCBI

25 

González D, Grilló MJ, De Miguel MJ, Ali T, Arce-Gorvel V, Delrue RM, Conde-Alvarez R, Muñoz P, López-Goñi I, Iriarte M, Marín CM, Weintraub A, Widmalm G, Zygmunt M, Letesson JJ, Gorvel JP, Blasco JM and Moriyón I: Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One. 3:e27602008.

26 

Allen CA, Adams LG and Ficht TA: Transposon-derived Brucella abortus rough mutants are attenuated and exhibit reduced intracellular survival. Infect Immun. 66:1008–1016. 1998.PubMed/NCBI

27 

Ried JL and Collmer A: An nptI-sacB-sacR cartridge for constructing directed, unmarked mutations in gram-negative bacteria by marker exchange-eviction mutagenesis. Gene. 57:239–246. 1987. View Article : Google Scholar : PubMed/NCBI

28 

Christian RHR and Chris W: Lipopolysaccharide endotoxins. Annu Rev Biochem. 71:635–700. 2002. View Article : Google Scholar

29 

Grilló MJ, Blasco JM, Gorvel JP, Moriyón I and Moreno E: What have we learned from brucellosis in the mouse model? Vet Res. 43:292012.PubMed/NCBI

30 

Skyberg JA, Thornburg T, Rollins M, Huarte E, Jutila MA and Pascual DW: Murine and bovine γδT cells enhance innate immunity against Brucella abortus infections. PLoS One. 6:e219782012.

31 

Li X and He Y: Caspase-2-dependent dendritic cell death, maturation and priming of t cells in response to Brucella abortus infection. PLoS One. 7:e435122012. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Wang X, Yan G, Zhang R, Lang X, Yang YL, Li X, Chen S, Qian J and Wang X: Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19. Mol Med Rep 9: 653-658, 2014.
APA
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X. ... Wang, X. (2014). Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19. Molecular Medicine Reports, 9, 653-658. https://doi.org/10.3892/mmr.2013.1810
MLA
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X., Chen, S., Qian, J., Wang, X."Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19". Molecular Medicine Reports 9.2 (2014): 653-658.
Chicago
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X., Chen, S., Qian, J., Wang, X."Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19". Molecular Medicine Reports 9, no. 2 (2014): 653-658. https://doi.org/10.3892/mmr.2013.1810
Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Yan G, Zhang R, Lang X, Yang YL, Li X, Chen S, Qian J and Wang X: Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19. Mol Med Rep 9: 653-658, 2014.
APA
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X. ... Wang, X. (2014). Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19. Molecular Medicine Reports, 9, 653-658. https://doi.org/10.3892/mmr.2013.1810
MLA
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X., Chen, S., Qian, J., Wang, X."Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19". Molecular Medicine Reports 9.2 (2014): 653-658.
Chicago
Wang, X., Yan, G., Zhang, R., Lang, X., Yang, Y., Li, X., Chen, S., Qian, J., Wang, X."Immunogenic response induced by wzm and wzt gene deletion mutants from Brucella abortus S19". Molecular Medicine Reports 9, no. 2 (2014): 653-658. https://doi.org/10.3892/mmr.2013.1810
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team